ERR1 Antibody

What is ERR1 and what biological processes does it regulate?

ERR1 (Estrogen Receptor-Related Receptor alpha) functions as a key transcriptional regulator of energy metabolism genes, including the medium-chain acyl CoA dehydrogenase (MCAD), which plays a pivotal role in mitochondrial β-oxidation . Despite its name suggesting relation to estrogen receptors, ERR1 is an orphan nuclear receptor that functions without a known endogenous ligand. ERR1 is involved in controlling energy expenditure, lipid metabolism, and mitochondrial biogenesis, making it particularly important in tissues with high energy demands such as skeletal muscle. PGC-1β (Peroxisome proliferator-activated receptor gamma coactivator 1-beta) can function as a protein ligand of ERR, contributing to the control of energy balance in vivo . The receptor's activity contributes to metabolic fitness and has been investigated for potential implications in obesity resistance and athletic performance enhancement.

How do I determine the specificity of my ERR1 antibody?

When determining ERR1 antibody specificity, a multi-method validation approach is essential for reliable research outcomes. Begin with Western blotting against both recombinant ERR1 protein and endogenous expression in tissues known to express ERR1 highly (skeletal muscle, heart). Cross-reactivity testing is critical due to the significant sequence homology between ERR family members (ERR1, ERR2, ERR3); therefore, parallel testing with recombinant proteins for all three ERR variants is recommended. Immunoprecipitation followed by mass spectrometry provides definitive validation, confirming that your antibody captures the expected ERR1 protein and identifying any non-specific interactions . For spatial specificity confirmation, immunohistochemistry in ERR1-expressing tissues compared with ERR1-knockout models or tissues serves as a powerful verification method. Additionally, chromatin immunoprecipitation (ChIP) validation is valuable, as proper ERR1 antibodies should enrich for known ERR response elements in target genes such as MCAD . Proper validation increases confidence in experimental observations and reduces the possibility of misattributing results to ERR1 when they might stem from cross-reactivity with other ERR family members.

What controls should I include when using ERR1 antibodies in immunological assays?

Implementing comprehensive controls is essential for ERR1 antibody-based assays. Always include a positive control utilizing tissues or cell lines with confirmed high ERR1 expression (skeletal muscle or cardiac tissue are excellent options), verifying appropriate molecular weight detection (~55 kDa for ERR1). Negative controls should incorporate tissues from ERR1 knockout models when available, or alternatively, tissues with minimal ERR1 expression. Isotype controls matching your ERR1 antibody's host species and immunoglobulin class are critical for distinguishing specific binding from background signals, particularly in flow cytometry or immunohistochemistry applications . Peptide competition assays, where excess immunizing peptide blocks specific antibody binding, provide powerful evidence of binding specificity. For more rigorous validation, include siRNA or CRISPR-mediated ERR1 knockdown samples to demonstrate signal reduction proportional to protein depletion. When performing chromatin immunoprecipitation assays, include both positive control primers (targeting known ERR1 binding sites in genes like MCAD) and negative control primers (targeting genomic regions lacking ERR response elements) . This multi-layered control strategy ensures reliable distinction between specific ERR1 detection and non-specific or artifactual signals.

What is the optimal fixation method for ERR1 immunohistochemistry?

The optimal fixation method for ERR1 immunohistochemistry depends on the specific tissue properties and downstream applications. For most applications, 4% paraformaldehyde fixation for 24-48 hours provides the best balance between antigen preservation and tissue morphology. This method effectively cross-links proteins while maintaining ERR1 epitope accessibility. When working with tissues containing high lipid content (such as adipose tissue where ERR1 plays metabolic roles), a shorter fixation time (12-24 hours) prevents excessive hardening and antigen masking. For certain applications requiring superior morphological preservation, 10% neutral buffered formalin may be used, though this typically requires more rigorous antigen retrieval steps. Heat-mediated antigen retrieval in citrate buffer (pH 6.0) for 20 minutes typically yields optimal ERR1 epitope recovery after formalin fixation. Cold acetone fixation (10 minutes at -20°C) offers an alternative for frozen sections when rapid processing is required or when working with particularly sensitive epitopes. Regardless of fixation method, verification through parallel processing of known ERR1-positive tissues (skeletal muscle or heart) ensures that your chosen fixation protocol maintains antibody reactivity with the target protein while preserving tissue architecture for accurate localization studies.

How can I distinguish between different ERR family members in my experiments?

Distinguishing between ERR family members (ERR1/α, ERR2/β, ERR3/γ) requires a multi-faceted approach due to their significant sequence homology. At the antibody level, selecting highly validated monoclonal antibodies targeting non-conserved regions is essential; specifically, antibodies raised against the N-terminal A/B domain show greatest specificity as this region exhibits minimal conservation across ERR subtypes . Verification through Western blot analysis using recombinant proteins of all three ERR variants as controls is crucial for confirming subtype specificity. When designing RT-qPCR assays, primers should target unique exon junctions, and specificity should be validated using plasmids containing each ERR subtype. For protein interactions, supershift assays in electrophoretic mobility shift experiments provide clear discrimination, as demonstrated with PGC-1β interaction studies . Chromatin immunoprecipitation followed by sequencing (ChIP-seq) offers genome-wide binding profiles that can distinguish ERR subtypes based on their unique binding patterns, despite overlapping target genes. For functional studies, selective pharmacological modulators can be employed: XCT790 selectively antagonizes ERR1, while GSK5182 preferentially targets ERR3. When analyzing knockout or knockdown experiments, monitoring the compensatory expression changes in other ERR family members is essential for accurate interpretation, as functional redundancy exists within this nuclear receptor family. This comprehensive approach ensures reliable discrimination between ERR subtypes in complex experimental systems.

How do post-translational modifications affect ERR1 antibody recognition?

Post-translational modifications (PTMs) significantly impact ERR1 antibody recognition through multiple mechanisms that can enhance or impair epitope accessibility. ERR1 undergoes several key modifications including phosphorylation (particularly at serine residues), SUMOylation, acetylation, and ubiquitination, each potentially masking or altering epitope structure. Phosphorylation of ERR1 at specific serine residues during cell signaling cascades can induce conformational changes that either expose or conceal antibody binding sites. When selecting antibodies for specific research questions, understanding the epitope location relative to known PTM sites is crucial. For detection of total ERR1 pools regardless of modification state, antibodies targeting highly conserved regions distant from known modification sites are preferable . Conversely, modification-specific antibodies can be powerful tools for studying ERR1 regulation, but require rigorous validation with appropriate controls (phosphatase-treated samples for phospho-specific antibodies). To comprehensively study ERR1 in complex systems, employing multiple antibodies targeting different epitopes provides complementary data and reveals potential blind spots in PTM-rich environments. When unexpected results occur, consider whether experimental conditions might induce ERR1 modifications that affect antibody recognition; for instance, stress conditions may trigger PTMs that alter epitope accessibility, as observed with related nuclear receptors . This awareness of PTM effects on antibody recognition is essential for accurate data interpretation and experimental design in ERR1 research.

What are the best approaches for ERR1 chromatin immunoprecipitation (ChIP) assays?

Optimizing ERR1 chromatin immunoprecipitation (ChIP) assays requires careful consideration of several critical factors to ensure high specificity and sensitivity. Crosslinking optimization is the foundation of successful ERR1 ChIP; while standard protocols recommend 1% formaldehyde for 10 minutes, ERR1 may benefit from titrating between 0.75-1.25% formaldehyde and adjusting crosslinking times between 8-12 minutes to optimize signal-to-noise ratio. Antibody selection is particularly crucial - ChIP-validated antibodies targeting the DNA-binding domain or C-terminus generally perform better than those targeting the N-terminal region, which may be involved in cofactor interactions that mask epitopes . The chromatin fragmentation method significantly impacts success; sonication parameters should be optimized to achieve fragments between 200-500bp, with careful monitoring via gel electrophoresis to prevent over-sonication, which can destroy epitopes. Including both positive controls (primers targeting known ERR1 binding sites in the MCAD promoter) and negative controls (genomers lacking ERR response elements) is essential for validating specificity . For challenging experiments, a sequential ChIP approach incorporating initial immunoprecipitation with antibodies against PGC-1β followed by ERR1 can enhance specificity for active transcriptional complexes, as demonstrated by the interaction between these factors . When analyzing ChIP-seq data, motif enrichment analysis should confirm enrichment of the canonical ERR response element (TGACCT) to validate specificity. This comprehensive approach overcomes the technical challenges inherent to transcription factor ChIP assays, enabling reliable interrogation of ERR1 genomic binding patterns.

How can I assess ERR1 antibody cross-reactivity with other species for evolutionary studies?

Assessing ERR1 antibody cross-reactivity across species requires systematic validation approaches that leverage evolutionary conservation patterns. Begin with sequence alignment analysis of the ERR1 epitope region across target species using tools like Clustal Omega, calculating percent identity to predict potential cross-reactivity; generally, >85% epitope conservation suggests likely cross-reactivity. Western blot validation using tissue lysates from multiple species provides direct evidence of cross-reactivity while revealing species-specific molecular weight variations that may occur due to differential post-translational modifications or splice variants. The ideal validation tissue is skeletal muscle, as it consistently shows high ERR1 expression across vertebrates . When antibodies fail to recognize ERR1 in certain species despite high sequence homology, epitope masking by species-specific post-translational modifications should be considered. For immunohistochemical applications across species, a gradient of fixation conditions and antigen retrieval methods should be tested, as optimal conditions often vary between species even when the antibody successfully cross-reacts. Preparing a reference table documenting validated cross-reactivity, optimal conditions, and observed molecular weights for each species creates an invaluable resource for evolutionary studies. For the most rigorous validation, heterologous expression systems can be employed to express ERR1 from various species in a controlled cellular background, enabling direct comparison of antibody affinity across orthologues. This comprehensive approach ensures reliable interpretation of cross-species data when studying ERR1 evolutionary conservation or divergence.

What are the optimal ELISA conditions for ERR1 antibody detection?

Optimizing ELISA conditions for ERR1 antibody detection requires methodical parameter adjustment to achieve maximum sensitivity and specificity. For coating concentration, titrate recombinant ERR1 protein between 0.5-2.0 μg/ml in carbonate buffer (pH 9.6) to determine optimal antigen density; too little reduces sensitivity while excess can increase background . The blocking solution composition significantly impacts assay performance - 3% BSA in PBS typically provides superior results compared to milk-based blockers which may contain endogenous factors that interact with nuclear receptors. Primary antibody concentration should be determined through checkerboard titration, typically starting at 1:1000 and performing 2-fold serial dilutions; the optimal dilution provides maximum signal while maintaining low background. Incubation parameters significantly impact sensitivity - overnight incubation at 4°C generally yields superior results compared to shorter incubations at higher temperatures for nuclear receptor detection. For wash stringency, PBS-T (0.05% Tween-20) is typically sufficient, though increased Tween-20 concentration (0.1%) may be necessary if background persists. When analyzing results, the R-based ELISA analysis method offers advantages over traditional endpoint titer methods by identifying the highest dilution at which antibody effectively binds to antigen, reducing sample variability and providing more consistent results . For multiplexed analysis comparing ERR1 with related nuclear receptors, maintaining consistent conditions across all antigens is essential for valid comparisons. This systematic optimization approach ensures reliable quantification of ERR1 antibodies for applications ranging from basic research to more complex experimental systems.

How should I troubleshoot weak or non-specific ERR1 antibody signals?

Troubleshooting weak or non-specific ERR1 antibody signals requires systematic evaluation of multiple experimental parameters. For weak signals, first verify ERR1 expression in your sample using RT-qPCR, as expression levels vary significantly across tissues and cell types, with highest expression typically found in skeletal muscle, heart, and kidney. Epitope masking due to fixation is a common cause of weak signals; if using formalin-fixed tissues, extend antigen retrieval time and test alternative retrieval buffers (citrate pH 6.0 versus Tris-EDTA pH 9.0) . Primary antibody concentration should be titrated upward, and incubation time extended (overnight at 4°C) to enhance sensitivity for low-abundance proteins like ERR1. For persistent non-specific signals, first examine the molecular weight profile; ERR1 should appear at approximately 55 kDa, with additional bands potentially indicating degradation products or cross-reactivity with ERR2/3. Increase blocking stringency by using combination blockers (3% BSA with 10% normal serum matching your secondary antibody species) and extend blocking time to 2 hours at room temperature. Washing stringency can be increased by adding 0.1% instead of 0.05% Tween-20 to wash buffers and increasing wash durations. For immunohistochemistry applications, tissue-specific autofluorescence can be reduced using Sudan Black B (0.1% in 70% ethanol) treatment prior to secondary antibody application. When troubleshooting ERR1 antibodies in complex samples, consider testing multiple antibodies targeting different epitopes, as some regions may be inaccessible due to protein-protein interactions, particularly with coactivators like PGC-1β . This systematic approach identifies and addresses specific causes of suboptimal ERR1 antibody performance.

How can I differentiate between different isoforms of ERR1 in my experiments?

Differentiating between ERR1 isoforms requires strategic experimental design that exploits their structural and functional distinctions. At the transcript level, isoform-specific RT-qPCR provides primary differentiation capability; design primers spanning unique exon-exon junctions with validation using synthetic templates representing each isoform variant. At the protein level, Western blotting with high-percentage (10-12%) or gradient polyacrylamide gels can separate ERR1 isoforms based on small molecular weight differences. Antibody selection is critical - epitope-specific antibodies targeting regions present in some but not all isoforms enable selective detection; when such antibodies are unavailable, a combination of antibodies targeting different regions can provide complementary data for isoform identification . 2D gel electrophoresis offers superior resolution by separating isoforms based on both molecular weight and isoelectric point differences resulting from post-translational modifications. For functional studies, isoform-specific knockdown using siRNAs targeting unique regions of each variant, followed by phenotypic analysis, reveals distinct functional roles. ChIP-seq analysis can reveal isoform-specific genomic binding patterns when performed with isoform-specific antibodies or in cellular models expressing single isoforms. Mass spectrometry provides definitive isoform identification through detection of unique peptide sequences, with parallel reaction monitoring (PRM) offering targeted quantification of specific isoforms. When publishing research involving ERR1, clear specification of the isoform(s) studied is essential for result interpretation and reproducibility . This multi-method approach enables comprehensive differentiation of ERR1 isoforms in complex biological systems, enhancing our understanding of their distinct functional roles.

How do I interpret contradictory results between ERR1 antibody-based methods and other detection techniques?

Resolving contradictions between ERR1 antibody-based methods and alternative detection techniques requires systematic investigation of multiple potential explanations. Epitope accessibility variations frequently underlie such discrepancies; ERR1's interaction with cofactors like PGC-1β can mask antibody recognition sites while leaving detection by other methods unaffected . Post-translational modifications (phosphorylation, SUMOylation, acetylation) may alter antibody binding without affecting mRNA detection, creating apparent contradictions between protein and transcript measurements. When antibody results conflict with functional assays, consider that antibodies may detect both active and inactive forms of ERR1, while functional assays reveal only transcriptionally competent protein. Comparing the detection limits of each method is essential - transcript detection via qPCR typically offers greater sensitivity than antibody-based protein detection, potentially creating discrepancies in samples with low ERR1 expression. Sample preparation differences can generate contradictory results; nuclear proteins like ERR1 require specialized extraction protocols that may differ between methodologies. When antibody-based results conflict with mass spectrometry data, examine whether the antibody recognizes specific ERR1 isoforms or post-translationally modified variants that represent subsets of the total protein detected by MS. The temporal dimension must also be considered; rapid changes in ERR1 transcription may not immediately translate to protein level changes, creating time-dependent discrepancies between transcript and protein measurements. Rather than viewing contradictions as experimental failures, they often reveal important biological insights about ERR1 regulation that would remain hidden with single-method approaches. Resolving these contradictions through careful method comparison and validation enhances our understanding of ERR1 biology in complex systems.